Polycarboxylic Acid Patents (Class 514/566)
-
Patent number: 5362754Abstract: Disclosed are pharmaceutical compositions of a mixture of minocycline and EDTA (M-EDTA) and methods of using the compositions in maintaining the patency of a catheter port. Methods for inhibiting the formation of polysaccharide-rich glycocalyx (such as the glycocalyx of staphylococcal organisms) are also provided using an M-EDTA solution. The M-EDTA solution may also be used to pretreat a medical device to prevent adherence of infectious organisms, such as S. epidermidis and S. aureus. The compositions destroy and prevent the formation of polysaccharide-rich glycocalyx. Methods for treating infections of S. epidermidis and S. aureus where glycocalyx formation are provided with an M-EDTA solution. The minocycline and EDTA solutions are included together within a pharmacologically acceptable carrier solution, such as saline.Type: GrantFiled: November 12, 1992Date of Patent: November 8, 1994Assignee: Univ. of TX MD Anderson Cancer CenterInventors: Issam Raad, Robert J. Sherertz
-
Patent number: 5332579Abstract: A nutritional supplement, functioning as a food for special dietary use, enhances diets and assists persons recovering from addiction to health damaging substances. Since cellular damage and deficiencies occur and continue to exist even after the person has stopped abusing the substances, use of the nutritional supplement, which contains a variety of minerals, vitamins, herbs, amino acids, and other substances and nutrients, should be continuous. The nutritional supplement consists of a mixture of nutrients which cooperate synergistically in enhancing cellular metabolic pathways and assists in normalization of cellular functions and optimization of cellular health.Type: GrantFiled: November 20, 1992Date of Patent: July 26, 1994Inventor: Anthony J. Umbdenstock
-
Patent number: 5324747Abstract: Compounds of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, n, m, o, p and q are as hereinafter set forth, and, when R.sub.2 is hydrogen, pharmaceutically acceptable salts thereof with bases, are described. The compounds of formula 1 are potent inhibitors of phospholipases A.sub.2 (PLA.sub.2 's) and are therefore useful in the treatment of inflammatory diseases, such as psosiasis, inflammatory bowel disease, asthma, allergy, arthritis, dermatitis, gout, pulmonary disease, myocardial ischemia/reperfusion, and trauma induced inflammation, such as spinal cord injury.Type: GrantFiled: July 15, 1992Date of Patent: June 28, 1994Assignee: Hoffmann-La Roche Inc.Inventors: Mathew Carson, Ru-Jen L. Han, Ronald A. LeMahieu, Vincent S. Madison
-
Patent number: 5312831Abstract: The invention relates to novel ureas and urethanes of Formula I: ##STR1## which stimulate cytokine production and may be used to accelerate recovery from neutropenia accompanying radio- or chemotherapy, bone marrow transplantation, or infections. Compounds in the invention or pharmaceutical compositions employing these compounds may be useful in the treatment of cancer, AIDS, aplastic anemia, myelodysplastic syndrome, and infectious diseases, and in the enhancement of immune response.Type: GrantFiled: May 12, 1993Date of Patent: May 17, 1994Assignee: American Cyanamid CompanyInventors: Semiramis Ayral-Kaloustian, Steven R. Schow, Mila T. Du, James J. Gibbons, Jr.
-
Patent number: 5308627Abstract: A nutritional supplement, functioning as a food for special dietary use, enhances diets and assists persons recovering from addiction to health damaging substance(s). Since cellular damage and deficiencies occur and continue to exist even after the person has stopped abusing the substance(s), use of the nutritional supplement, which contains at least one enzyme activating substance and at least one enzyme cofactor, should be continuous. The nutritional supplement consists of a mixture of nutrients which cooperate synergistically in enhancing cellular metabolic pathways and assists in normalization of cellular functions and optimization of cellular health.Type: GrantFiled: November 19, 1992Date of Patent: May 3, 1994Inventor: Anthony J. Umbdenstock, Jr.
-
Patent number: 5296501Abstract: A compound selected from the group consisting of a compound of the formula ##STR1## wherein the dotted lines indicate an optionally endo or exo double bond, Y is selected from the group consisting of alkyl, alkenyl and alkynyl of 2 to 18 carbon atoms and alkyl of 1 to 18 carbon atoms substituted with at least one halogen, X, X' and X.sub.1 are individually selected from the group consisting of hydrogen, alkyl of 1 to 8 carbon atoms, alkenyl and alkynyl of 2 to 8 carbon atoms, aryl of 6 to 14 carbon atoms, aralkyl of 7 to 18 carbon atoms, acyl of a fatty acid and acyl of an .alpha. or .omega.-amino acid, n and/or n.sub.1 is 1 and R and/or R.sub.1 is the remainder of an amine or an .alpha. or .omega.-amino acid or n and/or n.sub.1 is 2 and R and R.sub.1 are selected from the group consisting of hydrogen, alkyl of 1 to 8 carbon atoms, aryl of 6 to 14 carbon atoms, aralkyl of 7 to 18 carbon atoms and ##STR2## R.sub.Type: GrantFiled: April 27, 1993Date of Patent: March 22, 1994Assignee: Roussel UclafInventors: Constantin Agouridas, Nicole Tessot, Annie Martel
-
Patent number: 5154903Abstract: This invention pertains to an improved method of inhibiting peroxide-reduction catalytic activity and concomitant toxicity of asbestos and nonasbestos iron-containing silicates. These undesirable reactions can be substantially reduced or essentially eliminated by contacting these potentially harmful materials with an aqueous solution comprising a non-mutagenic non-toxic iron chelating agent, such as phytic acid, diethylenetriamine pentaacetic acid (DTPA) or derivatives of these.Type: GrantFiled: September 13, 1990Date of Patent: October 13, 1992Assignees: Massachusetts General Hospital, Boston Biomedical Research InstituteInventors: Philip J. Graceffa, Sigmund A. Weitzman
-
Patent number: 5143732Abstract: An orally administered pharmaceutical agent that is particularly suited for iron and magnesium substitutive therapy is disclosed. This drug consists of a combination of one or more pharmaceutically and physiologically compatible iron compounds, one or more pharmaceutically and physiologically compatible magnesium compounds, and, if the magnesium compounds do not contain any chlorine atoms dissociable in aqueous media and saturating the available magnesium valences, the drug further consists of one or more pharmaceutically and physiologically compatible compounds providing chlorine ions in aqueous media. The iron compounds, magnesium compounds and chlorine ion supplying compounds may be mixed with the conventional pharmaceutical solvents and/or thinners and/or auxiliary matter. Unexpectedly, this drug makes it possible to simultaneously administer magnesium or calcium compounds with iron compounds, without thereby causing reduced iron resorption.Type: GrantFiled: March 15, 1989Date of Patent: September 1, 1992Assignee: Verla-Pharm Arzneimittelfabrik Apotheker H.J. V. Ehrlich GmbH & Co.Inventors: Joachim Helbig, Hans G. Classen
-
Patent number: 5122369Abstract: An orally acceptable nutrient and mineral supplement for reducing hair loss wherein the composition contains divalent iron and pantothenic acid in a weight to weight ratio of approximately 1-3 and racemic d, 1-methionine. A particularly preferred composition contains 11.25 mg. of divalent iron as ferrous fumarate and 35 mg. of pantothenic acid as calcium pantothenate and 200 mg. of d,1-methionine.Type: GrantFiled: April 16, 1991Date of Patent: June 16, 1992Assignee: Harmony Health Products, Inc.Inventor: R. Harvey Dye
-
Patent number: 5114974Abstract: The treatment of atherosclerosis by administration of pure MgNa.sub.2 EDTA to a patient to favorably influence one or more of the multiple stages in the complex pathophysiology of the disease.Type: GrantFiled: January 30, 1991Date of Patent: May 19, 1992Inventor: Martin Rubin
-
Patent number: 5108733Abstract: Spontaneous aspecific coloration in so-called Trinder reagents which can alter subsequent colorimetric determinations is inhibited by adding compounds of the chelating agent class to the solution. The resultant compositions contain a peroxidase enzyme, a phenylpyrazone derivative, a compound of phenolic or aromatic amine structure and a stabilizer. Preferred stabilizers are ethylenediaminetetraacetic acid (EDTA) and diethylenetriaminepentaacetic acid (DTPA).Type: GrantFiled: August 30, 1990Date of Patent: April 28, 1992Assignees: Instrumentation Laboratory S.p.A., 501 Instrumentation Laboratory S.p.A.Inventors: Dario Frontini, Maurizio D'Alterio
-
Patent number: 5106873Abstract: This invention relates to novel compounds which are ACAT inhibitors rendering them useful in lowering blood cholesterol levels. The compounds contain two urea or thiourea, amide, or amine moieties or combinations of said moieties and have the following general formula: ##STR1## wherein m and n are zero or one, W and YNH and ##STR2## form the urea, thiourea, amide or amine moieties; and R.sub.1 and R .sub.2 are hydrogen or a hydrocarbon radical.Type: GrantFiled: June 26, 1990Date of Patent: April 21, 1992Assignee: Warner-Lambert CompanyInventors: Patrick M. O'Brien, Drago R. Sliskovic, Michael W. Wilson
-
Patent number: 5047425Abstract: Compounds of the formula ##STR1## wherein Ar, R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, X and n have the meanings mentioned in the description, processes and intermediates for their preparation, pharmaceutical compositions which contain them and their use in therapy in the treatment of cardiovascular diseases.Type: GrantFiled: November 30, 1988Date of Patent: September 10, 1991Assignee: Simes Societa Italiana Medicinali & Sintetici SpAInventors: Cesare Casagrande, Francesco Santangelo, Luisa Calabi
-
Patent number: 5036052Abstract: There are herein disclosed stablized and/or dense L-amino acid nutrient compositions, i.e., amino acid infusion solutions, which contain at least one oligopeptide having at least one residue of L-Tryptophan, L-Tyrosine, L-Leucine, L-Isoleucine and L-Valine.Type: GrantFiled: June 21, 1989Date of Patent: July 30, 1991Assignees: Morishita Pharmaceutical Co., Ltd., Ajinomoto Co., Inc.Inventors: Kohji Ozeki, Yoshitsugu Tsukamoto, Hideya Yaginuma, Makoto Sato
-
Patent number: 5030658Abstract: Disclosed are arthropodicidal solutions for application to plants comprising, as an active ingredient, arthropodicidally active mono alpha carboxylic acids, of hydrocarbons having 8 to 20 carbon atoms, and/or monovalent metal salts thereof. The arthropodicidal activity of these fatty acids is potentiated by including in the solution an agent capable of sequestering metal ions such as one or a mixture of chelateing agents, sequestering agents, and surfactants.Type: GrantFiled: November 17, 1989Date of Patent: July 9, 1991Assignee: Safer, Inc.Inventors: Greg Salloum, George Puritch, Michelle Gorman, Roderick Bradbury
-
Patent number: 4988724Abstract: Disclosed are total parenteral nutrition formulations which include essential amino acids in combination with either arginine or ornithine, for use in the detection of recurrent malignant disease in patients. Such formulations stimulate tumor-specific polyamine production to a greater extent than non-tumor related polyamine production. Additionally, such formulations were found to specifically promote an increase in red blood cell putrescine levels of tumor-bearing rats. Nontumor-bearing rats were not found to be similarly reactive to these formulations. Methods for making and administering these formulations as well as their use in preventing DFMO-induced toxicity are also disclosed.Also disclosed are parenteral nutritional formulations which include both citrulline and ornithine which have an arginine concentration of less than about 0.10% by weight final concentration. These formulations inhibit tumor growth and are particularly suited to provide nutritional support for patients with malignant disease.Type: GrantFiled: December 9, 1988Date of Patent: January 29, 1991Assignee: Board of Regents, The University of Texas SystemInventors: Jaffer Ajani, Bruce Grossie, Jr., Kenji Nishioka, David M. Ota
-
Patent number: 4975281Abstract: In accordance with the present invention a novel oral composition and method of using same for the treatment of ulcers and other gastrointestinal disorders is disclosed. The composition comprises an agent capable of forming an ulcer-adherent protective complex in an acid environment combined with one or more alkaline materials in a total amount sufficient to substantially prevent the formation of such a complex in the mouth and adherence of such a complex to the buccal mucosa.Type: GrantFiled: January 30, 1989Date of Patent: December 4, 1990Assignee: E. R. Squibb & Sons, Inc.Inventors: Richard J. Harwood, Edward V. Henry, Joseph S. Sonk, Luke T. H. Foo, Jay L. Rheingold, Robert C. deGroof
-
Patent number: 4891356Abstract: A method of treating gastrointgestinal ulcer disease is provided which involves administration of a proteinase inhibitor or analogue to patients suffering from same. Of particular interest is the use of inhibitors of serine, cysteine, carboxyl, and metallo proteinases.Type: GrantFiled: July 15, 1987Date of Patent: January 2, 1990Assignee: Brigham & Women's HospitalInventor: Sandor Szabo
-
Patent number: 4859653Abstract: This invention relates to new compositions of matter for use in treating wrinkling of the human skin. The compositions comprise, as an essential ingredient therein, at least one N-acylate, by butyric acid, of an alpha-amino acid or a salt of said acylate with an inorganic, organic or biologic base or with a metal.Type: GrantFiled: December 9, 1986Date of Patent: August 22, 1989Inventors: Jean V. Morelle, Eliane M. T. Lauzanne-Morelle
-
Patent number: 4845125Abstract: An improved composition for dissolution of renal calculi is disclosed. The composition includes citric acid, preferably at about 10 to about 15% by weight, and an effective amount of a pharmacologically acceptable chelating agent such as EDTA in a sterile aqueous solution having a pH between about 3 and about 4.5. In vivo irrigation with the improved formulation, optionally in combination with incident ultrasound therapy promotes rapid stone dissolution with minimal complications for the patient.Type: GrantFiled: November 10, 1987Date of Patent: July 4, 1989Assignee: Indianapolis Center for Advanced Research, Inc.Inventor: George E. Geier
-
Patent number: 4814351Abstract: A scalp treatment for reducing average daily hair loss periodically applies to the scalp a composition containing an active chelating agent sufficient to chelate at least 0.3 milligrams of divalent calcium ion per milliliter of the composition and leaving the chelating agent in contact with the scalp for at least eight hours. Particularly preferred chelating agents comprise ethylene diamine tetraacetic acid, citric acid, and soluble salts thereof.Type: GrantFiled: June 26, 1987Date of Patent: March 21, 1989Assignee: Redken Laboratories, Inc.Inventors: Roger A. Mathews, David W. Cannell
-
Patent number: 4721726Abstract: A method for inhibiting the action of enkephalinases in a mammal to thereby elicit an analgesic effect in said mammal is described.Novel compound and compositions useful for accomplishing the method of the invention are also described.Type: GrantFiled: July 25, 1986Date of Patent: January 26, 1988Assignee: Schering CorporationInventor: Joel G. Berger
-
Patent number: 4695588Abstract: Novel substituted .alpha.-fluoromethyl-.alpha.-amino alkanoic acids and esters thereof are disclosed. The novel compounds have biological activity including decarboxylase inhibition.Type: GrantFiled: March 16, 1978Date of Patent: September 22, 1987Assignee: Merck & Co., Inc.Inventors: Janos Kollonitsch, Arthur A. Patchett
-
Patent number: 4689347Abstract: A new pharmaceutical composition is disclosed useful in the treatment of neuroviruses and formulated as an injectable solution. The pharmaceutical composition is composed of the calcium and sodium double salt of ethylene diamine tetracetic acid, associated with calcium gluconate as a source of Ca.sup.2+ ions, and cysteine or its HC1 salt, wherein the weight ratio of the ingredients ranges from 8-12 g to 0.3 to 1 g to 0.05 to 0.2 g respectively per 100 ml of water.Type: GrantFiled: October 10, 1985Date of Patent: August 25, 1987Assignee: Centrala Industriala de Medicamente Cosmetice Coloranti Si LacuriInventors: Romulus C. Dinu, Illeana D. Dinu
-
Patent number: 4668665Abstract: A storage-stable sucralfate-containing preparation which maintains its ability, even after extended periods of time, to form a viscous, sticky, paste-like material in the presence of gastric secretions is disclosed as well as the method of making same.Type: GrantFiled: September 10, 1985Date of Patent: May 26, 1987Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Kouji Ishihara, Kazuo Igusa, Toshichika Ogasawara
-
Patent number: 4661510Abstract: Novel .alpha.-allenic-.alpha.-amino acids which are enzyme inhibitors of the suicide or k.sub.cat type are disclosed herein.Type: GrantFiled: October 21, 1985Date of Patent: April 28, 1987Assignee: Syntex (U.S.A.) Inc.Inventors: Alexander Krantz, Arlindo L. Castelhano
-
Patent number: 4584404Abstract: Selective biogenic amine uptake inhibitors, 3-substituted phenyloxy-3-phenylpropyldimethylamines.Type: GrantFiled: October 24, 1983Date of Patent: April 22, 1986Assignee: Eli Lilly and CompanyInventors: Bryan B. Molloy, Klaus K. Schmiegel
-
Patent number: 4496588Abstract: A novel method of treating psoriasis which comprises administering a halomethyl derivative of .alpha.-amino acids of the following general structure: ##STR1## wherein Y is FCH.sub.2 --, F.sub.2 CH--, F.sub.3 C--, ClCH.sub.2 --, Cl.sub.2 CH--; Z is .gamma.-guanidinopropyl or R.sub.a HN(CH.sub.2).sub.n -- wherein n is the integer 3 or 4; each of R.sub.a and R.sub.b can be the same or different and is hydrogen, alkylcarbonyl wherein the alkyl moiety has from 1 to 4 carbon atoms and is straight or branched, alkoxycarbonyl wherein the alkoxy moiety has from 1 to 4 carbon atoms and is straight or branched, or ##STR2## wherein R.sub.2 is hydrogen, a straight or branched lower alkyl group of from 1 to 4 carbon atoms, benzyl or p-hydroxybenzyl; R.sub.1 is hydroxy; a straight or branched alkoxy group of from 1 to 8 carbon atoms, --NR.sub.4 R.sub.5 wherein each of R.sub.4 and R.sub.5 is hydrogen or a lower alkyl group of from 1 to 4 carbon atoms, or ##STR3## wherein R.sub.Type: GrantFiled: April 28, 1983Date of Patent: January 29, 1985Assignee: Merrell Toraude et CompagnieInventors: Philippe Bey, Michel Jung